Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
clinical evaluation
MedTech
Blue Earth’s Axumin study shows promise in glioma PET scans
A phase 3 study from imaging firm Blue Earth Diagnostics found that its Axumin contrast agent for PET scans could assist in glioma diagnoses.
Conor Hale
Nov 19, 2018 11:25am
Congenica chosen to provide genomics software to NHS initiative
Oct 19, 2018 11:05am
CTTI seeks to prevent investigator ‘one and done’ syndrome
Oct 11, 2017 5:29pm
China may relax trial requirements for new drugs
Oct 9, 2017 9:22am
Japanese biopharma scopes out deal with Seattle bioelectronics startup
Aug 4, 2016 8:54am
